Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs Investment will support Odyssey’s portfolio of clinical and preclinical medicines designed to precisely treat the drivers of complex autoimmune diseasesJeito will leverage its global network, expertise and strong value creation track record in immunology and inflammation to support Odyssey for the benefit of pa ...